Administration-dependent efficacy of ferrociphenol lipid nanocapsules for the treatment of intracranial 9L rat gliosarcoma

Int J Pharm. 2012 Feb 14;423(1):55-62. doi: 10.1016/j.ijpharm.2011.04.037. Epub 2011 Apr 21.

Abstract

The anti-tumour effect of ferrociphenol (FcdiOH)-loaded lipid nanocapsules (LNCs), with or without a DSPE-mPEG2000 coating, was evaluated on an orthotopic gliosarcoma model after administration by convection-enhanced delivery (CED) technique or by intra-carotid injection. No toxicity was observed by MRI nor by MRS in healthy rats receiving a CED injection of FcdiOH-LNCs (60μL, 0.36mg of FcdiOH/rat) when the pH and osmolarity had been adjusted to physiological values prior to injection. At this dose, the treatment by CED with FcdiOH-LNCs significantly increased the survival time of tumour-bearing rats in comparison with an untreated group (28.5 days vs 25 days, P=0.0009) whereas DSPE-mPEG2000-FcdiOH-LNCs did not exhibit any efficacy with a median survival time of 24 days. After intra-carotid injection (400μL, 2.4mg of FcdiOH/rat), hyperosmolar DSPE-mPEG2000-FcdiOH-LNCs markedly increased the median survival time (up to 30 days, P=0.0008) as compared to the control (20%). This was strengthened by their evidenced accumulation in the tumour zone and by the measure of the fluorescent brain surface obtained on brain slides for these DiI-labelled LNCs, being 3-fold higher than for the control. These results demonstrated that, depending upon the administration route used, the characteristics of LNC suspensions had to be carefully adapted.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / therapeutic use
  • Brain / metabolism
  • Brain / pathology
  • Brain Neoplasms / drug therapy*
  • Brain Neoplasms / pathology
  • Drug Carriers / chemistry
  • Drug Carriers / toxicity
  • Female
  • Ferrous Compounds / administration & dosage*
  • Ferrous Compounds / therapeutic use*
  • Fluorescent Dyes / administration & dosage
  • Fluorescent Dyes / metabolism
  • Gliosarcoma / drug therapy*
  • Gliosarcoma / pathology
  • Hydrogen-Ion Concentration
  • Infusions, Parenteral / methods
  • Injections, Intra-Arterial
  • Kaplan-Meier Estimate
  • Lipids / chemistry*
  • Magnetic Resonance Imaging
  • Magnetic Resonance Spectroscopy
  • Nanocapsules / chemistry*
  • Nanocapsules / toxicity
  • Osmolar Concentration
  • Particle Size
  • Phosphatidylethanolamines / chemistry
  • Plant Lectins / chemistry
  • Polyethylene Glycols / chemistry
  • Rats
  • Rats, Inbred F344
  • Soybean Proteins / chemistry
  • Static Electricity
  • Stearic Acids / chemistry
  • Treatment Outcome
  • Triglycerides / chemistry

Substances

  • 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)
  • Antineoplastic Agents
  • Drug Carriers
  • Ferrous Compounds
  • Fluorescent Dyes
  • Lipids
  • Nanocapsules
  • Phosphatidylethanolamines
  • Plant Lectins
  • Soybean Proteins
  • Stearic Acids
  • Triglycerides
  • ferrociphenol
  • soybean lectin
  • Polyethylene Glycols
  • Solutol HS 15